Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen from SARS-CoV-2

Amrish Mehta, Bri Spencer, Ashok Garg, Pradeep Kalmorge, Raúl A. Ocasio Gonzalez, Kate Taussig, Ryan R. Fortna
doi: https://doi.org/10.1101/2022.03.23.22272094

Article Information

doi 
https://doi.org/10.1101/2022.03.23.22272094
History 
  • March 23, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Amrish Mehta1,
  2. Bri Spencer2,
  3. Ashok Garg3,
  4. Pradeep Kalmorge4,
  5. Raúl A. Ocasio Gonzalez5,
  6. Kate Taussig5 and
  7. Ryan R. Fortna2,*
  1. 1Apple Diagnostics, Ghatkopar, Mumbai
  2. 2Northwest Laboratory, Bellingham, WA, USA
  3. 3Acu-MDx Laboratory and Research Center Pvt. Ltd Diagnostics, Ghatkopar West, Mumbai
  4. 4Bio Diagnostics Laboratory, Pune
  5. 5Hemex Health, Portland, USA
  1. ↵*Correspondence:
    Ryan R. Fortna, Email: Ryan.Fortna{at}nwpathology.com, 3548 Meridian Street, Suite 101, Bellingham, WA 98225, (360) 527-4580
Back to top
Posted March 23, 2022.
Download PDF
Data/Code
Email
Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen from SARS-CoV-2
Amrish Mehta, Bri Spencer, Ashok Garg, Pradeep Kalmorge, Raúl A. Ocasio Gonzalez, Kate Taussig, Ryan R. Fortna
medRxiv 2022.03.23.22272094; doi: https://doi.org/10.1101/2022.03.23.22272094
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area